New Data, New Studies, New Hopes for Renal Denervation in Patients with Uncontrolled Hypertension

Overview

Journal Int J Cardiol Hypertens

Specialty Cardiology & Vascular Diseases

Date 2021 Jan 15

PMID 33447752

Authors

Vasilios Papademetriou

Konstantinos Stavropoulos

Kostas Imprialos

Michael Doumas

Roland E Schmieder

Atul Pathak

Costas Tsioufis

Affiliations

Soon will be listed here.

Abstract

Background: following the publication of SYMPLICITY HTN-3 the field of renal of denervation was put on hold. Although SYMPLICITY HTN-3 was well-designed and sham-controlled trial it failed to show any meaningful reduction in office or 24 h ambulatory blood pressure. The procedure was however safe and allowed research to continue. Although several pitfalls of the study have been pointed out, incomplete renal denervation was also implicated. Since then, a great deal of basic and clinical research took place and will be briefly commented on in this article.

Methods And Results: Before and after SYMPLICITY-HTN-3, numerous uncontrolled, single or unblinded studies have shown substantial office BP reduction ranging from -7.7 to -32 mmHg and ambulatory BP ranging from -2.2 to 10.2 mmHg. Average weighted office systolic BP reduction was -20.8 mmHg and weighted average 24 h ambulatory BPM reduction was -7.8 mmHg. National and international registries have shown similar BP reductions, but results remained unconvincing due to lack of reliable sham controls. In recent years, 5 well-designed sham - controlled studies (beyond, SYMPLICITY-HTN-3) have been published. Of those studies two were single center and three were multicenter international studies. Four studies used single tip or multi-electrode, radiofrequency catheters and one used focused ultrasound. The three multicenter studies reported positive-placebo subtracted results and established BP reductions measured both in the office and by ambulatory monitoring. No serious adverse events were reported.

Conclusions: It can therefore be concluded that the latest sham controlled studies established efficacy and safety of renal denervation.

References

Denegri A, Naduvathumuriyil T, Luscher T, Sudano I . Renal nerve ablation reduces blood pressure in resistant hypertension: Long-term clinical outcomes in a single-center experience. J Clin Hypertens (Greenwich). 2018; 20(4):627-633. PMC: 8030853. DOI: 10.1111/jch.13252. View

de Jager R, de Beus E, Beeftink M, Sanders M, Vonken E, Voskuil M . Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension. 2017; 69(4):678-684. DOI: 10.1161/HYPERTENSIONAHA.116.08818. View

Fischell T, Fischell D, Ghazarossian V, Vega F, Ebner A . Next generation renal denervation: chemical "perivascular" renal denervation with alcohol using a novel drug infusion catheter. Cardiovasc Revasc Med. 2015; 16(4):221-7. DOI: 10.1016/j.carrev.2015.04.008. View

Papademetriou V, Rashidi A, Tsioufis C, Doumas M . Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation. 2014; 129(13):1440-51. DOI: 10.1161/CIRCULATIONAHA.113.005405. View

Kandzari D, Bohm M, Mahfoud F, Townsend R, Weber M, Pocock S . Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018; 391(10137):2346-2355. DOI: 10.1016/S0140-6736(18)30951-6. View

Jacobs L, Persu A, Huang Q, Lengele J, Thijs L, Hammer F . Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017; 26(6):321-331. DOI: 10.1080/08037051.2017.1320939. View

Schmieder R, Mahfoud F, Azizi M, Pathak A, Dimitriadis K, Kroon A . European Society of Hypertension position paper on renal denervation 2018. J Hypertens. 2018; 36(10):2042-2048. DOI: 10.1097/HJH.0000000000001858. View

Iliescu R, Lohmeier T, Tudorancea I, Laffin L, Bakris G . Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015; 309(7):F583-94. PMC: 4593817. DOI: 10.1152/ajprenal.00246.2015. View

Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler D . Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014; 64(7):635-43. DOI: 10.1016/j.jacc.2014.03.059. View

10.

Desch S, Okon T, Heinemann D, Kulle K, Rohnert K, Sonnabend M . Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015; 65(6):1202-8. DOI: 10.1161/HYPERTENSIONAHA.115.05283. View

11.

Tsioufis C, Ziakas A, Dimitriadis K, Davlouros P, Marketou M, Kasiakogias A . Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry. Clin Res Cardiol. 2016; 106(5):322-330. DOI: 10.1007/s00392-016-1056-z. View

12.

Mahfoud F, Edelman E, Bohm M . Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy?. J Am Coll Cardiol. 2014; 64(7):644-6. DOI: 10.1016/j.jacc.2014.05.037. View

13.

Schmieder R, Ott C, Toennes S, Bramlage P, Gertner M, Dawood O . Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. J Hypertens. 2017; 36(3):680-689. DOI: 10.1097/HJH.0000000000001584. View

14.

Bohm M, Mahfoud F, Ukena C, Hoppe U, Narkiewicz K, Negoita M . First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015; 65(4):766-74. DOI: 10.1161/HYPERTENSIONAHA.114.05010. View

15.

Howard J, Cole G, Sievert H, Bhatt D, Papademetriou V, Kandzari D . Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014; 172(1):29-35. DOI: 10.1016/j.ijcard.2013.12.183. View

16.

Azizi M, Schmieder R, Mahfoud F, Weber M, Daemen J, Davies J . Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018; 391(10137):2335-2345. DOI: 10.1016/S0140-6736(18)31082-1. View

17.

Fengler K, Rommel K, Blazek S, Besler C, Hartung P, von Roeder M . A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). Circulation. 2018; 139(5):590-600. DOI: 10.1161/CIRCULATIONAHA.118.037654. View

18.

Townsend R, Mahfoud F, Kandzari D, Kario K, Pocock S, Weber M . Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390(10108):2160-2170. DOI: 10.1016/S0140-6736(17)32281-X. View

19.

Mathiassen O, Vase H, Bech J, Christensen K, Buus N, Schroeder A . Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016; 34(8):1639-47. PMC: 4933576. DOI: 10.1097/HJH.0000000000000977. View

20.

Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A . Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2013; 28(3):150-6. PMC: 3932403. DOI: 10.1038/jhh.2013.88. View